Table 4.
Univariate and multivariate analysis of parameters associated with the risk of ncRILD
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI | p value | OR | 95%CI | p value | |
| Sex, male versus female | 1.51 | 0.16–13.88 | 0.716 | |||
| Age (years) | 1.02 | 0.96–1.08 | 0.558 | |||
| Bodyweight (kg) | 1.03 | 0.98–1.08 | 0.216 | |||
| Radiographic liver cirrhosis | 0.83 | 0.28–2.45 | 0.735 | |||
| Hepatitis etiology | ||||||
| Hepatitis B virus | 1.03 | 0.19–5.49 | 0.973 | |||
| Hepatitis C virus | 0 | 0.00-Inf | 0.991 | |||
| Other | 1.41 | 0.25–8.03 | 0.696 | |||
| ECOG PS | ||||||
| 0 | Reference | – | – | |||
| 1 | 1.06 | 0.30–3.78 | 0.931 | |||
| 2 | 0 | 0.00-Inf | 0.992 | |||
| Total bilirubin (μmol/L), > 21 versus ≤ 21 | 1.38 | 0.47–4.09 | 0.556 | |||
| Albumin (g/L), ≥ 35 versus < 35 | 4,751,306 | 0.00-Inf | 0.991 | |||
| PT (sec), > 13 versus ≦ 13 | 4.60 | 1.34–15.85 | 0.016 | 4.15 | 1.11–15.53 | 0.035 |
| Child–Pugh score | ||||||
| 7 | Reference | – | – | |||
| 8 | 0.58 | 0.12–2.96 | 0.516 | |||
| 9 | 1.61 | 0.14–19.08 | 0.707 | |||
| ALBI score | 1.16 | 0.25–5.38 | 0.849 | |||
| ALBI Grade, 2 versus 3 | 1.78 | 0.52–6.11 | 0.359 | |||
| AST (U/L), > 40 versus ≤ 40 | 1.00 | 0.30–3.26 | 0.994 | |||
| ALT (U/L), > 40 versus ≤ 40 | 0.91 | 0.31–2.70 | 0.871 | |||
| ALP (U/L), > 150 versus ≤ 150 | 2.95 | 0.92–9.47 | 0.068 | |||
| WBC (10^12/L), ≥ 4 versus < 4 | 1.48 | 0.4–5.48 | 0.56 | |||
| HGB (g /L), ≥ 110 versus < 110 | 1.69 | 0.55–5.17 | 0.359 | |||
| PLT (10^9/L), ≥ 100 versus < 100 | 1.17 | 0.28–4.90 | 0.833 | |||
| ANC (10^9/L), ≥ 2 versus < 2 | 2.89 | 0.58–14.45 | 0.195 | |||
| ALC (10^9/L), ≥ 0.8 versus < 0.8 | 0.68 | 0.2–2.39 | 0.551 | |||
| Alpha fetoprotein (ng/ml), < 400 versus ≥ 400 | 1.21 | 0.41–3.56 | 0.735 | |||
| Max tumor size (cm) | 1.02 | 0.92–1.14 | 0.686 | |||
| Tumor number, ≥ 3 versus < 3 | 5.68 | 1.19–27.15 | 0.029 | 5.84 | 1.12–30.29 | 0.036 |
| Macrovascular invasion, yes versus no | 2.27 | 0.58–8.88 | 0.237 | |||
| Extrahepatic metastasis, yes versus no | 1.89 | 0.63–5.65 | 0.257 | |||
| BCLC stage | ||||||
| A | Reference | – | – | |||
| B | 42,544,812 | 0.00-Inf | 0.991 | |||
| C | 13,347,392 | 0.00-Inf | 0.992 | |||
| Dose per fraction, Gy, ≥ 2.7 versus < 2.7 | 1.95 | 0.61–6.25 | 0.261 | |||
| GTV (cc/ml), ≥ 257.9 versus < 257.9 | 1.58 | 0.49–5.07 | 0.445 | |||
| EQD28 (Gy), ≥ 54.3 versus < 54.3 | 1.29 | 0.42–3.98 | 0.653 | |||
| NLV (cc/ml), ≥ 565.2 versus < 565.2 | 4,837,693 | 0.00-Inf | 0.991 | |||
| Dmean (Gy), ≥ 15.1 versus < 15.1 | 4.00 | 1.16–13.74 | 0.028 | 4.31 | 1.14–16.28 | 0.031 |
| Prior treatment | ||||||
| TACE | 1.13 | 0.32–4.02 | 0.846 | |||
| RFA | 0.66 | 0.07–6.09 | 0.716 | |||
| Surgical resection | 0.50 | 0.15–1.74 | 0.278 | |||
| Systemic therapy | 0.97 | 0.27–3.45 | 0.959 | |||
ALBI, albumin–bilirubin; ALC, absolute lymphocyte count; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; Dmean, mean dose to the normal liver; ECOG PS, Eastern Cooperative Oncology Group-performance status; EQD2, equivalent dose in 2‑Gy fractions; GTV, gross tumor volume; HGB, hemoglobin; NLV, normal liver volume; OR, odds ratio; PLT, platelets; PT, prothrombin time; RFA, radiofrequency ablation; RT, radiotherapy; TACE, transcatheter chemoembolization; WBC, white blood cells; 8, using LQ model, α/β = 8 Gy